Diabetes (2011) 60(12):31039.10.2337/db11-0979 97 ChristensenMCalannaSSparre-UlrichAHKristensenPLRosenkildeMMFaberJet alGlucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes
In the U.S., 12% of adults say they are currently using a GLP-1 drug, up from 6% who said the same in 2024, according to a KFF survey
Triple agonists that are being developed to target three Gs (GLP-1, GIP, and glucagon) may also help increase metabolism
60 Currently, there is no discussion regarding the differential efficacy of different doses of liraglutide in the treatment of MASLD
Thrive GLP-1, manufactured by Le-Vel as part of their myGLP system, sits somewhere in the middle, a legitimate supplement with real ingredients but effectiveness nowhere near prescription semaglutide or tirzepatide
References 1 BaronADSchaefferLShraggPKoltermanOG